Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 4:21:100579.
doi: 10.1016/j.jvacx.2024.100579. eCollection 2024 Dec.

Association between vaccination and persistent COVID-19-related symptoms among patients with mild Omicron infection: A prospective cohort study

Marciane Maria Rover  1   2   3 , Fernando Luis Scolari  1   2 , Geraldine Trott  1 , Mariana Motta Dias da Silva  4 , Denise de Souza  1 , Rosa da Rosa Minho Dos Santos  1 , Raíne Fogliati De Carli Schardosim  1 , Emelyn de Souza Roldão  1 , Gabriel Pozza Estivalete  1 , Gabriela Soares Rech  1 , Duane Mocellin  1 , Jennifer Menna Barreto de Souza  1 , Aline Paula Miozzo  1 , Carolina Rothmann Itaqui  1 , Gabrielle Nunes da Silva  1 , Juliana de Mesquita Neto  1 , Hellen Jordan Martins Freitas  1 , Catherine Vitória Pereira Dos Santos  1 , Alanys Santos da Silveira  1 , Carla Moura D'Ávila  1 , Christian Morais Soares  1 , João Vítor Gozzi  1 , Ingrid Flor Dos Santos  1 , Sidiclei Machado Carvalho  5 , Vivian Menezes Irineu  6 , Odilson Marcos Silvestre  7 , Kênia do Carmo Marinho Borges  8 , Precil Diego Miranda de Menezes Neves  9 , Fernando Azevedo Medrado Junior  10 , Juliana Carvalho Schleder  11 , Thiago Pelissari Dos Santos  12 , Estêvão Lanna Figueiredo  13 , Benedito Antonio Lopes da Fonseca  14 , Sérgio Luiz Zimmermann  15 , Mauricio Antonio Pompilho  16 , Luciane Maria Facchi  17 , Otavio Celso Eluf Gebara  18 , Milena Soriano Marcolino  19   20 , Ana Carolina Peçanha Antonio  21 , Paulo R Schvartzman  2 , Bruna Brandao Barreto  22   23 , Caroline Cabral Robinson  1 , Maicon Falavigna  24   20 , Luiz Antônio Nasi  5   25 , Carisi Anne Polanczyk  2   3   4   5   21   20 , Andreia Biolo  2   3   5   21   20 , Regis Goulart Rosa  1   5   25
Affiliations

Association between vaccination and persistent COVID-19-related symptoms among patients with mild Omicron infection: A prospective cohort study

Marciane Maria Rover et al. Vaccine X. .

Erratum in

  • Corrigendum to Association between vaccination and persistent COVID-19-related symptoms among patients with mild Omicron infection: A prospective cohort study.
    Rover MM, Scolari FL, Trott G, da Silva MMD, de Souza D, Santos RDRMD, Schardosim RFC, de Souza Roldão E, Estivalete GP, Rech GS, Mocellin D, de Souza JMB, Miozzo AP, Itaqui CR, da Silva GN, de Mesquita Neto J, Freitas HJM, Santos CVPD, da Silveira AS, D'Ávila CM, Soares CM, Gozzi JV, Santos IFD, Carvalho SM, Irineu VM, Silvestre OM, do Carmo Marinho Borges K, de Menezes Neves PDM, Junior FAM, Schleder JC, Santos TPD, Figueiredo EL, da Fonseca BAL, Zimmermann SL, Pompilio MA, Facchi LM, Gebara OCE, Marcolino MS, Antonio ACP, Schvartzman PR, Barreto BB, Robinson CC, Falavigna M, Nasi LA, Polanczyk CA, Biolo A, Rosa RG. Rover MM, et al. Vaccine X. 2024 Dec 19;22:100603. doi: 10.1016/j.jvacx.2024.100603. eCollection 2025 Jan. Vaccine X. 2024. PMID: 39968079 Free PMC article.

Abstract

Background: While COVID-19 vaccination has been shown to reduce the risk of severe illness, its impact on the occurrence of persistent symptoms in patients with mild Omicron infection remains uncertain. Our objective was to investigate whether COVID-19 vaccination reduces the occurrence of persistent COVID-19-related symptoms 3 months after mild Omicron infection.

Methods: Multicenter prospective cohort study was conducted in Brazil between January 2022 and June 2023 when Omicron was predominant. Participants ≥ 18 years seeking outpatient care for symptomatic SARS-CoV-2 infection were enrolled. Complete vaccination included individuals who received the full primary series and any booster dose, while incomplete vaccination included those with incomplete primary series or no vaccination. The primary outcome was any persistent symptoms at 3 months. Secondary outcomes were organ system-specific persistent symptoms and the EQ-5D-3L utility score. All outcomes were assessed by means of structured telephone interviews 3 months after enrollment.

Results: 1,067 patients were enrolled (median age, 39 years), of which 914 (871 completely vaccinated and 43 unvaccinated or incompletely vaccinated). Among the vaccinated participants the median time since the last vaccine dose was 145 (interquartile range, 106-251) days. A total of 388/1067 (36.9 %) had a prior infection at the time of study entry. The occurrence of overall persistent COVID-19-related symptoms at 3 months was 41.6 % (n = 362) among completely vaccinated and 44.2 % (n = 19) among unvaccinated or incompletely vaccinated patients (adjusted risk ratio [aRR], 0.87; 95 % confidence interval [CI], 0.61-1.23; p = 0.43). Complete vaccination was associated with lower occurrence of mental health symptoms (aRR, 0.44; 95 % CI, 0.24-0.81; p = 0.01). No differences were found in the occurrence of persistent symptoms in other specific domains, nor in EQ-5D-3L utility scores.

Conclusions: This study was not able to identify a statistically significant protection of complete COVID-19 vaccination against any overall persistent symptoms at 3 months. Nevertheless, complete vaccination was associated with a lower occurrence of persistent mental health symptoms.

Keywords: COVID-19 vaccine; COVID-19 vaccine booster shot; Post-Acute COVID-19 Syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors MMR, FLS, GT, MMDS, DS, RRMS, RFCS, ESR, GPE, GSR, DM, JMBS, APM, CRI, GNS, JMN, HJMF, CVPS, ASS, CMD, CMS, JVP and IFS work at Hospital Moinhos de Vento, which received a research grant from the Brazilian Ministry of Health for the conduction of this study. RGR and MF had received research grants from the Brazilian Ministry of Health, Pfizer and MSD. All other authors declare that they have no conflict of interest. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Study flowchart.
Fig. 2
Fig. 2
Proportion of occurrence of symptoms reported at 3-month follow-up1.
See this image and copyright information in PMC

References

    1. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. apps.who.int [Internet]. 2021. Available from: https://apps.who.int/iris/handle/10665/345824.
    1. WHO. Coronavirus disease (COVID-19): Post COVID-19 condition. www.who.int [Internet]. 2021. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-dis....
    1. Dennis A., Wamil M., Alberts J., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11(3):e048391. - PMC - PubMed
    1. Rahmani K., Shavaleh R., Forouhi M., et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Front Public Health. 2022;10 doi: 10.3389/fpubh.2022.873596. - DOI - PMC - PubMed
    1. Simon M.A., Luginbuhl R.D., Parker R. Reduced incidence of long-COVID symptoms related to administration of COVID-19 vaccines both before COVID-19 diagnosis and up to 12 weeks after. Medrxiv. 2021 Nov 18 doi: 10.1101/2021.11.17.21263608. - DOI

LinkOut - more resources